# SAR448851 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sar448851

> The next catalyst for SAR448851, sponsored by Sanofi (SNY), is its topline data readout, Jul to Oct 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SAR448851 |
| Codes | SAR448851 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | Dementia, Alzheimer's Type |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Dementia, Alzheimer's Type; Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07688213 (A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07688213

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Dementia, Alzheimer's Type; Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07688213 (A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07688213

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sar448851.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SAR448851 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sar448851

```bibtex
@misc{secapidev_pdufa_sar448851_20261116,
  title        = {SAR448851 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sar448851}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sar448851_20261116","title":"SAR448851 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sar448851","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
